

100 years of *Mycobacterium bovis* bacille Calmette-Guérin

Christoph Lange, Peter Aaby, Marcel A Behr, Peter R Donald, Stefan H E Kaufmann, Mihai G Netea, Anna M Mandalakas



Mycobacterium bovis bacille Calmette-Guérin (BCG), an experimental vaccine designed to protect cattle from bovine tuberculosis, was administered for the first time to a newborn baby in Paris in 1921. Over the past century, BCG has saved tens of millions of lives and has been given to more humans than any other vaccine. It remains the sole tuberculosis vaccine licensed for use in humans. BCG provides long-lasting strong protection against miliary and meningeal tuberculosis in children, but it is less effective for the prevention of pulmonary tuberculosis, especially in adults. Evidence mainly from the past two decades suggests that BCG has non-specific benefits against non-tuberculous infections in newborn babies and in older adults, and offers immunotherapeutic benefit in certain malignancies such as non-muscle invasive bladder cancer. However, as a live attenuated vaccine, BCG can cause localised or disseminated infections in immunocompromised hosts, which can also occur following intravesical installation of BCG for the treatment of bladder cancer. The legacy of BCG includes fundamental discoveries about tuberculosis-specific and non-specific immunity and the demonstration that tuberculosis is a vaccine-preventable disease, providing a foundation for new vaccines to hasten tuberculosis elimination.

Introduction

Tuberculosis is the leading cause of death by a bacterial infectious disease worldwide.¹ Global tuberculosis control is limited by the absence of a vaccine that effectively protects people exposed to *Mycobacterium tuberculosis* from infection and disease.¹ The only vaccine licensed for the prevention of tuberculosis is *Mycobacterium bovis* bacille Calmette-Guérin (BCG), a vaccine based on attenuation of bacteria naturally causing tuberculosis in cattle, other animals, and occasionally humans. Analogous to the development of the smallpox vaccine by Edward Jenner in 1796, Léon Charles Albert Calmette (1863–1933; a physician) and Jean-Marie Camille Guérin (1872–1961; a veterinarian) applied the *similia similibus curenitur* (like cures like) principle to develop a tuberculosis vaccine (figure 1). First administered to a neonate in Paris in 1921,² BCG has probably been administered to more humans than any other vaccine for the prevention of infectious disease. In 2019, 88% of children globally received BCG vaccination during their first year of life.³ The BCG vaccine offers greater than 70% protection against disseminated tuberculosis and tuberculous meningitis in neonates and school-age children. Nevertheless, vaccine efficacy is much lower in adults.⁴ In addition to preventing tuberculosis and reducing tuberculosis-specific morbidity and mortality, epidemiological studies show non-specific benefits of childhood BCG vaccination for prevention of other communicable and non-communicable diseases and improved overall survival.^{5–7} The mechanism underlying these heterologous or non-specific effects, mediated by a combination of trained innate and adaptive immunity, has only begun to be unravelled.^{8–10}

In celebration of the 100th anniversary of BCG use in humans, we provide a historical review of the development and application of the BCG vaccine and a perspective on the current status of and future prospects for tuberculosis vaccination.

The origin of BCG: from Koch's tuberculin to BCG

Robert Koch's identification of *M tuberculosis* as the causative agent of tuberculosis in 1882 clearly demarcated

a new era.¹¹ Nevertheless, only in 1901 did Koch accept that two different organisms caused human and bovine tuberculosis (*M tuberculosis* vs *M bovis*). Although it was clear that *M bovis*-contaminated cow's milk caused a substantial proportion of tuberculosis cases, notably in young children, Koch considered *M bovis* transmission from cattle to humans to be negligible. More serious was Koch's 1890 claim to have discovered a tuberculosis vaccine, termed tuberculin, that he considered effective for tuberculosis prevention and therapy.¹¹ Tuberculin was a concentrated liquid culture of *M tuberculosis* with bacteria removed by filtration; today it would be defined as a subunit vaccine comprising *M tuberculosis* proteins and glycolipids serving as antigen and adjuvant, respectively. Unfortunately, in numerous clinical studies, tuberculin was ineffective. Emil von Behring, Koch, and their colleagues attempted to reduce the virulence of *M tuberculosis* without success.^{2,12–14} Mycobacteria from

Lancet Infect Dis 2021

Published Online
September 7, 2021
[https://doi.org/10.1016/S1473-3099\(21\)00403-5](https://doi.org/10.1016/S1473-3099(21)00403-5)

Division of Clinical Infectious Diseases, Medical Clinic, Research Center Borstel, Borstel, Germany (Prof C Lange); German Center for Infection Research (DZIF) Tuberculosis Unit, Borstel, Germany (Prof C Lange); Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany (Prof C Lange); Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA (Prof C Lange, Prof A M Mandalakas MD); Bandim Health Project, InDEPTH Network, Bissau, Guinea-Bissau (Prof P Aaby MD); Bandim Health Project, Southern Danish University, Copenhagen, Denmark (Prof P Aaby); McGill International TB Centre and Department of Medicine, McGill University, Montreal, QC, Canada (Prof M A Behr MD); Desmond Tutu TB Centre, Department of Paediatrics and




Figure 1: The founders of BCG
Jean-Marie Camille Guérin (1872–1961), left, and Léon Charles Albert Calmette (1863–1933), right.

Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa (Prof P R Donald MD); Max Planck Institute for Infection Biology, Berlin, Germany (Prof S H E Kaufmann PhD); Max Planck Institute for Biophysical Chemistry, Göttingen, Germany (Prof S H E Kaufmann); Hagler Institute for Advanced Study, Texas A&M University, College Station, TX, USA (Prof S H E Kaufmann); Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands (Prof M G Netea MD); Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany (Prof M G Netea)

Correspondence to: Prof Christoph Lange, Division of Clinical Infectious Diseases, Medical Clinic, Research Center Borstel, 23845 Borstel, Germany clange@fz-borstel.de

other host species, including avian-derived bacilli or mycobacteria derived from cold-blooded animals, such as turtles or blind worms, were investigated, but their efficacy was low and short-lived.^{2,15} Researchers repeatedly failed to inactivate experimental vaccines by heat, chemical treatment, and solvents.^{2,16,17}

Calmette and Guérin finally concluded that the only way forward was development of a live attenuated vaccine. They followed the strategy developed by their mentor, Louis Pasteur, of performing serial passages of the bacterium on a medium thought to affect virulence and testing the success of attenuation in animal models.¹⁸ In 1906, development of BCG began with the treatment of *M bovis* with ox bile that altered the appearance of the bacilli.² When *M bovis* was cultured on potato slices soaked with ox bile and glycerine, the dry-crumby colonies became smooth with a greenish-brownish colour. The mycobacteria grew on these solid cultures for 3–4 weeks; thereafter, transfer to new cultures was required. Accordingly, between 1908 and 1920, Calmette and Guérin renewed their cultures every 3 weeks, reaching 230 passages in 1920. The resulting strain was innocuous for a variety of animal species usually susceptible to *M bovis*. During these years, the bacterium lost a nine-gene locus (encoding for proteins Rv3871, PE35, PPE68, ESAT-6, CFP-10, Rv3876, Rv3877, Rv3878, and Rv3879c), referred to as region of difference 1 (RD1) as it is present in virulent *M bovis* and absent from all BCG strains.¹⁹ Gene complementation and gene deletion studies have confirmed the importance of the RD1 locus for full virulence of the bacterium.^{19–21} In addition to being of reduced virulence, the bacterium—when injected intravenously—protected cattle against challenge infection for approximately 1·5 years, especially newborn calves.² Even high bacillary doses were safe in guinea pigs, rabbits, and non-human primates. Although tuberculosis foci developed in the lungs, lymph nodes, liver, and spleen, caseation was never observed and pathological alterations soon resolved. Ultimately, efficacy trials in animals revealed that multidose oral administration held the greatest promise.²

On the basis of these observations, on July 18, 1921, Calmette, Guérin, and Benjamin Weill-Hallé performed the first vaccination of a neonate.² The neonate received three 2 mg BCG doses suspended in milk; neither disease nor adverse events developed during the subsequent 5·5 years. Between July, 1921, and July, 1922, 120 additional infants were vaccinated and the vaccination schedule evolved to three 1 mg applications every second day within 10 days post-birth (total $1\cdot2\times 10^9$ bacilli). BCG vaccination initially targeted newborn babies living in tuberculosis-affected families. By Feb 1, 1927, 21 200 infants had received BCG vaccination.² 1 year later, the intradermal route, still used today, was found to be more reliable because it allowed precise and reproducible dosing²² (of note, oral delivery of BCG is still used to control tuberculosis in both domestic livestock and

wildlife²³). Moreover, intradermal administration was found to induce 100% tuberculin skin test conversion with a reduction of 10–15% over 5 years. By contrast, oral application induced 40–85% conversion with a loss of 40–60% over 1 year.²⁴

Calmette observed that among 8075 vaccinated children mortality was only 4·6%, whereas among non-vaccinated children it was at least 16%; this finding suggested that BCG not only reduced tuberculosis-specific mortality but also substantially reduced all-cause infant mortality. In a 1931 lecture, Calmette provided two speculative explanations for the higher general mortality in non-vaccinated versus vaccinated neonates: first, “Can it be that tuberculous infection plays a more important part in infant mortality than we have supposed?” Or second, “...does the harbouring of BCG, followed by its digestion and elimination, confer on the organism a special aptitude to resist those other infections which are so frequent in young children?”²⁵

Although it is possible that tuberculous infections might have been underdiagnosed, the second alternative describing protection against other infections appears more intriguing and foreshadowed later observations of BCG’s heterologous or non-specific protection.

The Lübeck disaster

By 1929, in France alone, approximately 250 000 neonates had received oral BCG without noticeable adverse events. However, strong concerns remained that reversion to pathogenicity of any live vaccine was an ever-present threat.²⁶ During the second half of 1929, George Deycke and Ernst Altstaedt, the medical personnel responsible for tuberculosis control in Lübeck, Germany, requested a supply of BCG from Calmette for an immunisation programme targeting infants born into tuberculosis-endemic environments.

After delivery, the vaccine was unfortunately stored and processed in a hospital laboratory where virulent *M tuberculosis* was also stored. During the spring of 1930, BCG vaccination was offered to all 412 newborn babies in Lübeck. Tragically, 251 of these newborn babies received oral BCG that had been inadvertently contaminated by virulent *M tuberculosis*. Subsequently, the majority of them developed tuberculosis and 72 infants died from this (figure 2).²⁷

An in-depth assessment of the disaster, coordinated by Albert Moegling,²⁷ found no evidence that BCG had reverted to pathogenicity; the disaster was rather the consequence of negligent contamination of BCG.²⁸

Different BCG strains: current vaccination policies

Following demonstration of BCG safety and efficacy in France in the 1920s, there was global interest in introducing BCG to countries with a high prevalence of tuberculosis. The introduction of BCG faced challenges such as identifying the target population and ensuring consistent manufacturing.²⁹ From a production

standpoint, one key challenge was that BCG was not a defined biochemical entity; it was a living, mutating microbe propagated in the laboratory by transferring clumps of bacteria at regular intervals into fresh media.³⁰

The donor laboratory (Institut Pasteur) propagated BCG until 1961 and provided unique passage numbers with each BCG lot sent to requesting laboratories, where it was grown on non-standardised culture media. Hence, BCG was mutating both at the Institut Pasteur and at other BCG production laboratories worldwide for 40–50 years³¹ (depending on when laboratories created lyophilised seed lots), resulting in genetically distinct BCG strains.^{32,33} This early history of BCG propagation leads to three pertinent questions: (1) are BCG strains phenotypically different in the laboratory; (2) do different BCG strains have similar rates of adverse effects; and (3) do different BCG strains confer differing levels of protection?

A number of phenotypic differences have been noted between BCG strains, when conducting in-vitro biochemical analyses.^{34,35} For some strains, the responsible mutation has been causally identified.^{36,37} For others, an in-vitro phenotype has been noted but not confidently assigned to one specific mutation. As an example of the latter, a higher concentration of isoniazid is required to inhibit BCG-Denmark growth in the laboratory; the clinical significance of this remains undetermined.³⁸ Some of the in-vitro variants have been subject to in-vivo study in experimental infection models. While it is clear that licensed BCG vaccines differ markedly in their content of viable mycobacteria, possibly contributing to formulation-dependent activation of innate and adaptive immunity and distinct protective effects,³⁹ it has not been shown that this affects protection afforded against an *M tuberculosis* challenge.⁴⁰

Although genetic sequencing has conclusively documented that BCG strains are different³³ and distinct levels of virulence might be explained by strain-specific duplications and deletions of genomic DNA,⁴¹ a more pressing concern is whether BCG strains behave differently in the more than 100 million infants vaccinated each year. Natural experiments in strain-change have been associated with higher or lower rates of adverse events,⁴² but changes have also been seen when the same strain is made by a different producer.⁴³ Likewise, natural experiments of BCG strain-change have been associated with fluctuations in the rate of childhood tuberculosis, but clinical trials looking at protection against tuberculosis that used two strains are few, and none have directly compared early BCG strains that produce antigenic proteins, such as MPT64, MPT70, and MPT83, with late strains that fail to make these proteins (table 1). Currently, India uses both an early strain (BCG-Russia) and a late strain (BCG-Denmark); pharmacosurveillance in this large country with a high tuberculosis burden might provide data on relative rates of adverse effects and disease.




Figure 2: The unfolding of the BCG disaster in Lübeck in 1930

Note that three of the 251 infants were vaccinated before the start of the BCG campaign on Feb 24, 1930.

National BCG vaccination policies vary broadly with respect to dosing and strains⁴⁷ and are catalogued in the BCG World Atlas.⁴⁸ Because studies have shown minimal or no evidence of additional benefit in the protection against tuberculosis or for overall survival from repeat BCG vaccination,⁴⁹ WHO does not recommend revaccination even if the tuberculin skin test is negative. Countries with a low tuberculosis prevalence might selectively vaccinate high-risk neonates, such as those born to mothers with pulmonary tuberculosis or into families originating from countries with high tuberculosis prevalence.

Prevention and reduction of morbidity and mortality

For the prevention of pulmonary tuberculosis, clinical trials have estimated BCG vaccine efficacy to range broadly from 0% in the Chingleput trial in south India (rate ratio 1.05, 95% CI 0.88–1.25)^{4,50} to 80% in the UK Medical Research Council trial (0.22, 0.16–0.31).^{4,51} There are many hypothesised reasons for this wide

For BCG World Atlas see
<http://www.bcgatlas.org>

	Current manufacturer(s) ⁴⁴	Produces antigenic proteins MPT64, MPT70, and MPT83 ⁴⁵	Produces the virulence lipids PDIM and PGL ⁴⁶	Efficacy in randomised trial ⁴
BCG-Russia	Microgen; Serum Institute of India	Yes	Yes	Not tested
BCG-Sofia	BulBio	Yes	Not reported	Not tested
BCG-Tokyo	Japan BCG laboratory	Yes	No	Not tested
BCG-Moreau	Fundação Ataulpho de Paiva	Yes	No	Not tested
BCG-Denmark	AJ Biologics; Green Signal Pharma	No	Yes	Variable (0–80%)
BCG-China	China National Biotec	Yes	Not reported	Not tested
BCG-Tice	Merck	No	Yes	Variable (0–90%)
BCG-Glaxo	Aventis Pasteur	No	No	~30%
BCG-Pasteur	ANLIS, Argentina; BioFarma, Indonesia; Pasteur Institute of Iran, Iran; Institute of Virology, Vaccines and Sera (Torlak), Serbia; Institut de Pasteur Tunis, Tunisia; Institute of Vaccines and Medical Biologicals, Vietnam	No	Yes	Variable (0–75%)

PDIM=phthiocerol dimycocerosates. PGL=phenolic glycolipid.

Table 1: Summary of currently produced BCG strains

	Age at vaccination	Study excluded tuberculin-reactive individuals	Efficacy* RR (95% CI)	Between-study heterogeneity (τ ²)
Infants	Neonatal	Assumed non-reactive	0.41 (0.29–0.58)	0.0065
Children	School age	Yes	0.26 (0.18–0.37)	0.048
Children	School age	No	0.59 (0.35–1.01)	0.095
Mixed community and institutional	Older than school age	Yes	0.88 (0.5–1.31)	0
Mixed community and occupational	Older than school age	No	0.81 (0.55–1.22)	0.091

Data are from Mangtani and colleagues' systematic review on protection against tuberculosis by BCG.⁴ RR=rate ratio. *Random effects within strata summary effect estimate.

Table 2: BCG efficacy against pulmonary tuberculosis stratified by age at vaccination and study design

variation, including age at and time since vaccination,^{52–55} sex,⁵⁶ risk of tuberculosis in the study population,⁵⁷ geographical latitude of the study setting,^{58,59} and study design.⁵⁵ The protective effect of BCG is inversely associated with age at vaccination, with neonatal vaccination affording greater protection than vaccination of older children and adults (table 2).⁴ Furthermore, BCG efficacy appears to be higher in studies that use tuberculin skin testing to stringently limit eligibility to participants with no evidence of previous *M tuberculosis* infection compared with studies that include participants with reactive tuberculin skin tests.⁴ There is a direct linear relationship between the protective effect of BCG and the distance of the study setting from the equator.^{4,59,60} The possible causes for this variation (eg, a higher prevalence of non-tuberculous mycobacteria in equatorial regions) remain speculative, and the explanation is likely to be multifactorial.⁵⁸

There is evidence indicating that BCG vaccination affords protection in high-risk populations in settings with a low burden of tuberculosis, while being a cost-effective strategy.^{61,62} Similarly, computer-simulated modelling suggests that, within the US population, tuberculosis elimination can be achieved through the use of targeted BCG vaccination combined with targeted preventive treatment.⁶³ Key assumptions in this model include low risks of *M tuberculosis* infection, multidrug-resistant tuberculosis, and HIV infection.

The greatest benefit of BCG immunisation, which drives its high cost-effectiveness, is prevention of paediatric tuberculosis, particularly extrapulmonary tuberculosis in young children.⁶⁴ In this age group, the potential impact of BCG is amplified due to children's high risk of progression to severe forms of tuberculosis.⁶⁵ The protective effect of vaccination against all forms of paediatric tuberculosis has been estimated at 0.74 (95% CI 0.62–0.83) in randomised controlled trials (RCTs), and 0.52 (0.38–0.64) in case-control studies.⁶⁶ When analysis is limited to laboratory-confirmed tuberculosis reported in case-control studies, estimated effectiveness against tuberculosis is 0.83 (0.58–0.93).⁶⁶ Among children without evidence of previous *M tuberculosis* infection, the protective effect of BCG increases to 0.92 (rate ratio 0.08 [0.03–0.25]).⁴ The greatest impact of BCG has been shown in infants, in whom the protective effect is 0.90 (rate ratio 0.10 [0.01–0.77])^{4,67,68} for the prevention of meningeal and miliary tuberculosis.

BCG also prevents primary infection with *M tuberculosis*. Among European children completing testing for latent infection with *M tuberculosis*, previous BCG vaccination was associated with a negative result (QuantiferON-TB Gold In-Tube: odds ratio [OR] 0.41, p<0.001; T-SPOT.TB: OR 0.41, p<0.001).⁶⁹ Among adults with recent household tuberculosis exposure, there was also a negative association between BCG vaccination and latent tuberculosis infection (adjusted OR 0.70, 95% CI 0.56–0.87; p=0.0017) yielding a vaccine efficacy of 0.30.⁷⁰ Although vaccine efficacy declined with time since vaccination, the prevalence of latent tuberculosis infection was lower among vaccinated than non-vaccinated participants, even 20 years or more after vaccination. Similarly, among adolescents in a tuberculosis high-risk setting, BCG revaccination reduced the rate of sustained QuantiferON-TB Gold In-Tube conversion with an efficacy of 0.45 (p=0.03).⁷¹

Complications of BCG applications

As a live vaccine, BCG can cause localised adverse reactions including hypersensitivity, abscess formation, and regional lymphadenitis when applied by intradermal injection.^{72–75} These complications are mostly self-limiting and rarely require surgical or medical interventions. The risk of regional suppurative lymphadenitis following intradermal vaccination of children younger than 1 year is less than five per 1000 in most countries (range 0.0006–36 cases per 1000).⁷⁶

Children who develop disseminated BCG infection usually have an underlying genetic or acquired immunodeficiency. The risk of disseminated BCG disease was 0.06–1.56 per million vaccinated children in the pre-HIV era.⁷⁷ Today, HIV infection is the most common cause for disseminated BCG disease in neonates. In a South African multicentre surveillance study, the pooled incidence for disseminated BCG disease in vaccinated children living with HIV was 992 (95% CI 567–1495) per 100 000.⁷⁸ After a decade of debate regarding the risk–benefit ratio of BCG in people living with HIV, WHO guidelines recommend that adults, children, and neonates living with HIV should receive BCG vaccination if they are stable on antiretroviral therapy.⁷⁹ Furthermore, the revised WHO guidelines recommend that in settings with high HIV and tuberculosis burden, all healthy neonates should receive a single dose of neonatal BCG.⁷⁹

BCG vaccination is one of the most common causes of death in children with primary immunodeficiencies worldwide,⁷⁴ with an overall lethality of 50% and higher.⁸⁰ Genetic risk factors include severe combined immune deficiency, chronic granulomatous disease, combined immunodeficiency, leukocyte adhesion deficiency type 1, and mendelian susceptibility to mycobacterial disease.^{81–85}

Intravesical BCG application is the preferred treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) and an optional treatment for intermediate-risk NMIBC.^{86,87} Intravesical BCG therapy of NMIBC can be complicated by local adverse events such as cystitis, bladder contracture, bladder ulceration, granulomatous balanitis, epididymo-orchitis, prostatitis, urethritis, and kidney infections, or systemic complications including mycotic aneurysms, granulomatous hepatitis, reactive arthritis, spondylitis, miliary tuberculosis (appendix p 1), and rarely (1 in 15 000 patients) sepsis.^{88–90} Treatment requires anti-tuberculosis therapy over 9 months or longer. Like other strains of *M bovis*, BCG is intrinsically resistant to pyrazinamide.⁹¹

Non-specific benefits of BCG vaccination

BCG immunotherapy induces initial complete response rates of 55–65% for high-risk NMIBCs and 70–75% for carcinoma in situ; however, 40% of patients will eventually relapse despite initially successful BCG immunotherapy.⁹² BCG is administered once a week for 6 weeks intravesically, followed by maintenance therapy for 1–3 years, depending on the risk of tumour progression. BCG induces a complex immunological cascade of innate and adaptive immune responses resulting in cell-mediated tumour-specific killing of urothelial carcinoma cells.⁹² Compared with BCG vaccination, the number of bacteria given for intravesical therapy is orders of magnitude greater (~10⁶ bacilli for vaccination; ~10⁹ bacilli for bladder cancer).

In the 1970s to 1980s, the measles vaccine was found to have major beneficial effect for non-measles-specific child survival.⁹³ Observational studies examining other childhood vaccines suggested that BCG also had major

non-specific benefits.^{94,95} Because neonatal BCG was recommended by WHO, it was impossible to test these benefits in RCTs. To circumvent observational bias, studies compared BCG-vaccinated children with and without a BCG scar⁶ and interpreted differences in mortality to reflect the non-specific benefits of effective versus ineffective BCG vaccination. BCG scarring was linked to the quality of vaccination (supervision, quantity, depth of vaccination, and BCG strain). In the most recent meta-analysis, BCG scarring was associated with a 52% (95% CI 38–63) reduction in infant mortality.⁵ It is, however, important to underline that the presence of the BCG scar could alternatively signify a stronger immune response itself, which could subsequently explain the association with improved outcome.

In Guinea-Bissau, recommendations against BCG vaccination of low-birthweight children created an opportunity for randomised trials. In three RCTs, random assignment to receive BCG-Denmark at hospital discharge was associated with a 38% (95% CI 17–54) reduction in neonatal mortality.⁹⁶ Similar effects were found for physician-diagnosed non-tuberculous disease in an RCT of BCG-Denmark in Uganda.⁹⁷ RCTs from intensive care units have not found similar non-specific effects,⁹⁸ possibly because of differences in BCG strain or cause-specific mortality. BCG's non-specific benefits primarily result from reduction in neonatal sepsis and respiratory infections.^{96,99} BCG also provides protection against leprosy (overall protective effect of 26% [95% CI 14–37] with an enhanced effect after revaccination),¹⁰⁰ non-tuberculous mycobacteria lymphadenitis (relative risk 0.04 [95% CI 0.01–0.21]),¹⁰¹ and Buruli ulcer (0.50 [0.37–0.69]).^{101–103}

Child survival is correlated with the quality of BCG vaccination, which is assessed by the size of early reactions, scarring, and tuberculin skin test responses.¹⁰⁴ BCG vaccination enhances non-specific effects for child survival.¹⁰⁵ Notably, non-specific effects are much stronger if the child's mother has a BCG scar.^{106,107}

BCG has the strongest effect on survival in the first months of life, when infants have received only two live vaccines—BCG and oral polio. Following vaccination with non-live vaccines, such as diphtheria-tetanus-pertussis (DTP), it becomes difficult to measure non-specific effects because live and non-live vaccines interact immunologically. WHO recommends neonatal BCG and the first of three doses of DTP at the age of 6 weeks. Administration of DTP after BCG reduces the non-specific benefits of BCG, and mortality is increased particularly for girls.¹⁰⁸ However, co-administration of BCG and DTP can partly rectify the interaction.¹⁰⁹ In four studies examining vaccine sequence (appendix p 2), simultaneous administration of BCG and DTP was associated with a 43% (95% CI 27–56) reduction in mortality compared with administration of DTP after BCG in accordance with WHO guidelines. Given the strong effects of BCG on child survival, vaccination coverage, age, and quality should be monitored. The

See Online for appendix

findings from these studies of BCG and DTP suggest that BCG might modify the immunological effects of other sequences of vaccines.

Research on non-specific effects has focused on childhood BCG, but there is growing interest in whether BCG administered in childhood affects adults and whether BCG's immune training used among adults can modify disease patterns. The largest study showed that BCG (together with vaccinia) was associated with 46% (95% CI 19–64) lower mortality from natural causes between 7 years and 45 years of age in Denmark.¹¹⁰ BCG has been shown to modify the course of diabetes and multiple sclerosis.^{111–113} Observations further suggest that BCG therapy lowers the incidence of Alzheimer's disease in patients with bladder cancer.¹¹⁴ BCG given to older adults has also been associated with major reductions in respiratory infections.¹¹⁵

Given the observed non-specific effects of BCG, discontinuation of BCG vaccination programmes in countries of low tuberculosis prevalence might substantially reduce these beneficial BCG effects as well. Furthermore, BCG has also been tested extensively against COVID-19 infection in more than 20 RCTs, the largest being the BRACE trial (NCT04327206) which aims to recruit more than 10000 health-care workers; in an RCT among older adults in Greece, BCG revaccination reduced the risk and severity of COVID-19, according to one manuscript that has not yet been peer reviewed.¹¹⁶

BCG vaccination and induction of heterologous T-cell and trained immunity

Although epidemiological evidence for non-specific beneficial effects of BCG has accumulated over the past century,¹¹⁷ the lack of a biological explanation hampers recognition of the importance of these effects. One suggested mechanism through which BCG vaccination might induce beneficial non-specific effects is activation of heterologous lymphocyte responses. Studies during the 1960s demonstrated cross-protection between unrelated bacterial pathogens,¹¹⁸ mediated by lymphocytes with an increased capacity for production of IFN- γ after BCG vaccination. Subsequently, macrophage activation induced by IFN- γ promoted innate immunity against a secondary infection.¹¹⁹ These experimental animal studies were later complemented by human studies reporting that BCG increases IFN- γ production by peripheral blood mononuclear cells upon stimulation with unrelated microorganisms.¹²⁰ However, these data cannot explain all these effects, and increasing evidence showed that innate immune cells are also able to build memory characteristics, termed trained immunity,¹²¹ which partially drive the heterologous protection induced by BCG.

Trained immunity induced by BCG results in improved cytokine (TNF, IL-1, IL-6) responses by monocytes and macrophages,¹²⁰ and more effective release of reactive oxygen species, antimicrobial proteases, and enhanced pathogen killing by neutrophils.¹²² To achieve long-term

effects, functional changes are also induced by BCG at the level of bone marrow progenitors of myeloid cells biasing towards myelopoiesis.^{123,124} The memory characteristics of innate immune cells can last for months and even years.¹²⁵ The molecular processes responsible for these effects are represented by changes in chromatin accessibility due to chemical processes at the DNA (methylation) and histone (methylation, acetylation) level, leading to more effective transcription of genes important for host defense¹²⁶ (figure 3).

Next-generation vaccines

Tuberculosis vaccine research and development has produced a number of novel vaccine candidates in the clinical trial pipeline with some encouraging results.^{24,128} Principally, vaccines target prevention of disease. This can be achieved in three ways, either by (1) preventing infection; (2) containing infection with dormant *M tuberculosis*; or (3) preventing recurrence in patients who have been cured of tuberculosis but who are at risk of reinfection or relapse. Vaccine strategies include inactivated or viable whole-cell vaccine approaches and subunit approaches comprising fusion proteins of selected antigens in combination with a strong T-cell stimulating adjuvant. All vaccines are considered as boost vaccines on top of BCG prime given to different age groups either before or after exposure to *M tuberculosis*; in addition, viable vaccines are also considered as BCG replacement vaccines given pre-exposure with *M tuberculosis* to neonates. Improved application regimes for BCG are being considered as well. A study in non-human primates revealed that intravenous administration of BCG induced profound, and in some cases sterilising, immunity against *M tuberculosis* challenge.¹²⁹ Moreover, a BCG revaccination trial showed approximately 50% prevention of infection as measured by sustained IFN- γ release assay conversion, which measures antigen-induced IFN- γ secretion.⁷¹ By contrast, immediate infection was not inhibited, indicating short-term survival of *M tuberculosis* which was subsequently terminated by host mechanisms—either innate immunity, or perhaps involving training or rapid mobilisation of acquired immune memory.

Major vaccine candidates are listed in the appendix (pp 3–4). Two adjuvanted subunit vaccines have reached an advanced stage of clinical assessment. Approximately 50% of active tuberculosis was prevented by the protein-adjuvant vaccine M72:AS01_e over a 3-year clinical trial period.¹³⁰ This trial comprised HIV-uninfected individuals with latent infection with *M tuberculosis*, and the result might not apply to interferon- γ release assay-negative, non-BCG-vaccinated individuals. The H56:IC31 vaccine candidate is another protein adjuvant formulation undergoing phase 2b testing of prevention of tuberculosis recurrence (NCT03512249).

RUTI is composed of detoxified fragments of *M tuberculosis* and is administered as a liposomal preparation for therapy in adjunct to canonical drug




Figure 3: Trained immunity induced by BCG

The accessibility of chromatin, in particular of promoters and enhancers, is modulated by BCG vaccination. Upon cellular activation of innate immune cells, histone chemical modifications (eg, methylation, acetylation) result in an increased accessibility for transcription factor binding and initiation of gene transcription. Upon elimination of the stimulus, many of these changes are lost, but some histone marks (such as methylation) are preserved, bookmarking the genes important for host defense. Upon reinfection, chromatin architecture changes and induction of gene transcription can take place more quickly and strongly in an antigen-independent manner. The enhanced chromatin accessibility and gene transcription result in an improved innate immune response after BCG vaccination. Adapted from Chumakov and colleagues.¹²⁷

treatment of tuberculosis; it is currently being evaluated in a phase 2a trial (NCT02711735).¹²⁸ DAR-901 is composed of inactivated *Mycobacterium obuense* and was found to be safe and well tolerated, but failed to prevent infection as determined by both immediate and sustained IFN- γ release in a phase 2b trial.¹³¹ The third inactivated vaccine is based on *Mycobacterium indicus pranii* and has already been licensed as a leprosy vaccine. It demonstrated safety in a subgroup of patients with tuberculosis and provided evidence for improved bacillary clearance as determined by sputum culture conversion.¹³² This candidate is currently being tested head-to-head with VPM1002 in household contacts of patients with newly diagnosed tuberculosis in India (Clinical Trials Registry India CTRI/2019/01/017026). VPM1002 is one of the two advanced viable vaccines. It is the only vaccine among all candidates in clinical evaluation that is based on BCG. It has been generated by exchanging the gene encoding urease C with the listeriolysin gene.¹³³ This genetic modification leads to several intracellular modifications in macrophages harbouring the vaccine, which increases immunogenicity of VPM1002 over BCG. After successful completion of phase 1 and 2 safety trials in adults and neonates^{134,135} and in addition to the above-mentioned head-to-head trial, VPM1002 is also undergoing phase 3 trials in previously drug-treated patients in India to assess for prevention of recurrence (NCT03152903) and in

neonates at different clinical trial sites in sub-Saharan Africa to assess for prevention of infection (NCT043451685). The other viable vaccine candidate is MTBVAC, a genetically attenuated *M tuberculosis* strain with two independent gene deletions that affect expression of a whole variety of virulence factors, but leave proteins of *M tuberculosis* (which are absent from *M bovis* BCG) unaffected. Following phase 1 and 2 trials that showed safety and immunogenicity in adults and neonates, MTBVAC is currently prepared for phase 3 efficacy trials in both age groups.^{136,137} Not only are different vaccine candidates being tested, but there are also novel regimes being considered, notably aerosol vaccination to activate mucosal immunity in the lung, the major portal of entry and site of residence of *M tuberculosis*.^{138–140}

Conclusion

During the past century, millions of lives have been saved by BCG vaccination due to the induction of antimycobacterial immunity and the prevention of tuberculosis, particularly its most severe forms. Lives have also potentially been saved by the non-specific effects of BCG vaccination on other infectious and non-communicable diseases. During the past decade, we have begun to unravel the molecular mechanisms of BCG's beneficial non-specific effects. 100 years after the

Search strategy and selection criteria

In April, 2021, a trained medical librarian did eight separate systematic literature searches, primarily using Ovid MEDLINE (MEDLINE on OvidSP) without the use of language or publication year filters. The concepts were developed using both controlled and natural languages. MeSH terms were used and keywords were gathered along with various synonyms. Search terms included “adverse reactions”, “Bacille Calmette Guérin”, “BCG”, “BCG-itis”, “bovine”, “Calmette”, “cattle”, “collateral benefit”, “coronavirus”, “COVID19”, “cow”, “cross protection”, “effectiveness”, “efficacy”, “drug-related side effects”, “Guérin”, “heterologous effect”, “immunogenicity”, “Lubeck disaster”, “Mycobacterium bovis”, “Mycobacterium tuberculosis”, “nonspecific effect”, “PPD”, “purified protein derivative”, “recombinant BCG vaccine”, “Robert Koch”, “SARS-CoV-2”, “strains”, “tuberculosis”, “tubercle bacillus”, “VPM1002”, “vaccine potency”, and “trained immunity”. The keywords were searched using the title, abstract, and keyword fields within the Ovid MEDLINE database. A “Humans” filter was used on all but the Lübeck disaster search. Searches deemed low in numbers were also run in the Embase database. For continuity, after translation, the searches were all run again in each database on May 6, 2021. Within EndNote citation manager, search results underwent automated and manual de-duplication. Thereafter, two authors (CL and AMM) manually reviewed titles to exclude literature not relevant to the topic. In addition, publications in the German, French, and English literature known to the authors were included and their references searched for relevant additional literature.

first human inoculation with BCG, we are close to improving tuberculosis vaccine effectiveness. The revitalisation of tuberculosis vaccine research and development programmes promises to propel our strides towards the WHO 2030 goal of reducing tuberculosis morbidity by 90% and mortality by 95%.¹⁴¹

Contributors

CL developed the concept and, together with AMM, did the systematic literature reviews. All authors contributed equally in drafting and revising the manuscript.

Declaration of interests

SHEK is coinventor of the tuberculosis vaccine VPM1002 and coholder of a patent licensed to Serum Institute of India, Pune, India. MGN is coholder of patents on trained immunity licensed to Trained Therapeutic Discovery. CL reports personal fees from Chiesi, Gilead, Janssen, Novartis, Oxford Immunotec, and Insmid, outside of the submitted work. All other authors declare no competing interests.

Acknowledgments

CL is supported by the German Center for Infection Research (DZIF). MAB is supported by a Canada Research Chair and receives funding from the Canadian Institutes for Health Research. AMM is supported by the US Center for Disease Control and Elimination, the US Department of Defense, and the US National Institutes of Health including their Fogarty International Center and National Institute of Allergy and Infectious Diseases. We thank Diane Schad and Stanley Pardos for their excellent help with the figures. We also thank Lara Ouellette, medical librarian, for her help with the literature search.

References

- 1 WHO. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
- 2 Calmette A, Guérin C, Boquet A, Nègre L. La vaccination préventive contre la tuberculose par le “BCG”. Paris: Masson, 1927.
- 3 Chard AN, Gacic-Dobo M, Diallo MS, Sodha SV, Wallace AS. Routine vaccination coverage—worldwide, 2019. *MMWR Morb Mortal Wkly Rep* 2000; 69: 1706–10.
- 4 Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis* 2014; 58: 470–80.
- 5 Benn CS, Roth A, Garly ML, et al. BCG scarring and improved child survival: a combined analysis of studies of BCG scarring. *J Intern Med* 2020; 288: 614–24.
- 6 Garly ML, Martins CL, Balé C, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? *Vaccine* 2003; 21: 2782–90.
- 7 Ahmed A, Rakshit S, Adiga V, et al. A century of BCG: impact on tuberculosis control and beyond. *Immunol Rev* 2021; 301: 98–121.
- 8 Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. *Cell* 2020; 181: 969–77.
- 9 O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? *Nat Rev Immunol* 2020; 20: 335–37.
- 10 Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. *Science* 2016; 352: aaf1098.
- 11 Kaufmann SH, Winau F. From bacteriology to immunology: the dualism of specificity. *Nat Immunol* 2005; 6: 1063–66.
- 12 Sjögren I. Präventive Maßnahmen in Lungentuberkulose: Pathogenese, Klinik, Therapie, Epidemiologie. In: Hein J, Kleinschmidt H, Uehlinger E, eds. *Handbuch der Tuberkulose*, Bd 2. Stuttgart: G Thieme Verlag, 1982; 9.1–9.27.
- 13 von Behring E. Tuberkulosebekämpfung. *Gesammelte Abhandlungen*. Bonn: A. Marcus & E. Webers Verlag, 1915: 209–46.
- 14 Koch R. Über die Immunisierung von Rindern gegen Tuberkulose. *Gesammelte Werke von Robert Koch*. Leipzig: Georg Thieme Verlag, 1912: 591–611.
- 15 Friedmann FF. Immunisierung gegen Tuberkulose. *Dtsch Med Wochenschr* 1903; 50: 953–54.
- 16 Rabinowitsch M. Schutzimpfung mit abgeschwächten Tuberkelbacillen. *Berliner Klinische Wochenschrift* 1913; 50: 114–15.
- 17 Loeffler F. Die Verwendung von trocken erhitzten Mikroorganismen und von solchen, die mit verdauenden Fermenten behandelt sind, als Antigene, unter besonderer Berücksichtigung der Tuberkelbazillen. *Dtsch Med Wochenschr* 1913; 39: 1025–29.
- 18 Pasteur M. An address on vaccination in relation to chicken cholera and splenic fever. *BMJ* 1881; 2: 283–84.
- 19 Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between *Mycobacterium bovis* BCG and virulent *M. bovis*. *J Bacteriol* 1996; 178: 1274–82.
- 20 Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines *Mycobacterium bovis* BCG and *Mycobacterium microti*. *Mol Microbiol* 2002; 46: 709–17.
- 21 Lewis KN, Liao R, Guinn KM, et al. Deletion of RD1 from *Mycobacterium tuberculosis* mimics bacille Calmette-Guérin attenuation. *J Infect Dis* 2003; 187: 117–23.
- 22 Wallgren A. Intradermal vaccinations with BCG virus: preliminary note. *J Am Med Assoc* 1928; 91: 1876–81.
- 23 Buddle BM, Vordermeier HM, Chambers MA, de Klerk-Lorist LM. Efficacy and safety of BCG vaccine for control of tuberculosis in domestic livestock and wildlife. *Front Vet Sci* 2018; 5: 259.
- 24 Kaufmann SHE. The TB vaccine development pipeline: present and future priorities and challenges for research and innovation. In: Migliori GB, Raviglione M, eds. *Essential tuberculosis*. Heidelberg: Springer Nature, 2021: 395–405.
- 25 Calmette A. Preventive vaccination against tuberculosis with BCG. *Proc R Soc Med* 1931; 24: 1481–90.
- 26 Petroff SA, Branch A. Bacillus Calmette-Guérin (B.C.G.): animal experimentation and prophylactic immunization of children. *Am J Public Health Nations Health* 1928; 18: 843–64.
- 27 Moegling A. Die “Epidemiologie” der Lübecker Säuglingstuberkulose. *Arbeiten a d Reichsges-Amt* 1935; 69: 1–24.
- 28 Lange L, Pescatore H. Bakteriologische Untersuchungen zur Lübecker Säuglingstuberkulose. *Arbeiten a d Reichsges-Amt* 1935; 69: 205–305.
- 29 Behr MA, Divangahi M, Schurr E. Lessons from Bacille Calmette-Guérin for SARS-CoV-2 vaccine candidates. *J Infect Dis* 2021; 223: 189–91.

- 30 Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. *Vaccine* 1999; 17: 915–22.
- 31 Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. *Science* 1999; 284: 1520–23.
- 32 Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. *Proc Natl Acad Sci USA* 2007; 104: 5596–601.
- 33 Abdallah AM, Hill-Cawthorne GA, Otto TD, et al. Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. *Sci Rep* 2015; 5: 15443.
- 34 Wiker HG, Nagai S, Hewinson RG, Russell WP, Harboe M. Heterogenous expression of the related MPB70 and MPB83 proteins distinguish various substrains of *Mycobacterium bovis* BCG and *Mycobacterium tuberculosis* H37Rv. *Scand J Immunol* 1996; 43: 374–80.
- 35 Minnikin DE, Minnikin SM, Dobson G, et al. Mycolic acid patterns of four vaccine strains of *Mycobacterium bovis* BCG. *J Gen Microbiol* 1983; 129: 889–91.
- 36 Behr MA, Schroeder BG, Brinkman JN, Slayden RA, Barry CE 3rd. A point mutation in the *mma3* gene is responsible for impaired methoxymycolic acid production in *Mycobacterium bovis* BCG strains obtained after 1927. *J Bacteriol* 2000; 182: 3394–99.
- 37 Charlet D, Mostowy S, Alexander D, Sit L, Wiker HG, Behr MA. Reduced expression of antigenic proteins MPB70 and MPB83 in *Mycobacterium bovis* BCG strains due to a start codon mutation in *sigK*. *Mol Microbiol* 2005; 56: 1302–13.
- 38 Arend SM, van Soelingen D. Low level INH-resistant BCG: a sheep in wolf's clothing? *Clin Infect Dis* 2011; 52: 89–93.
- 39 Angelidou A, Conti MG, Diray-Arce J, et al. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. *Vaccine* 2020; 38: 2229–40.
- 40 Ritz N, Dutta B, Donath S, et al. The influence of bacille Calmette-Guérin vaccine strain on the immune response against tuberculosis: a randomized trial. *Am J Respir Crit Care Med* 2012; 185: 213–22.
- 41 Zhang L, Ru HW, Chen FZ, et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. *Mol Ther* 2016; 24: 398–405.
- 42 Frankel H, Byberg S, Bjerregaard-Andersen M, et al. Different effects of BCG strains—a natural experiment evaluating the impact of the Danish and the Russian BCG strains on morbidity and scar formation in Guinea-Bissau. *Vaccine* 2016; 34: 4586–93.
- 43 Kröger L, Brander E, Korppi M, et al. Osteitis after newborn vaccination with three different Bacillus Calmette-Guérin vaccines: twenty-nine years of experience. *Pediatr Infect Dis J* 1994; 13: 113–16.
- 44 Cernuschi T, Malvoti S, Nickels E, Friede M. Bacillus Calmette-Guérin (BCG) vaccine: a global assessment of demand and supply balance. *Vaccine* 2018; 36: 498–506.
- 45 Abdallah AM, Hill-Cawthorne GA, Otto TD, et al. Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. *Sci* 2015; 5: 15443.
- 46 Chen JM, Islam ST, Ren H, Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. *Vaccine* 2007; 25: 8114–22.
- 47 Dierig A, Tebruegge M, Krivec U, Heining U, Ritz N. Current status of Bacille Calmette Guérin (BCG) immunisation in Europe—a ptnet survey and review of current guidelines. *Vaccine* 2015; 33: 4994–99.
- 48 Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. *PLoS Med* 2011; 8: e1001012.
- 49 Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. *Lancet* 2005; 366: 1290–95.
- 50 Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention: first report. *Bull World Health Organ* 1979; 57: 819–27.
- 51 Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. *BMJ* 1977; 2: 293–95.
- 52 Whittaker E, Nicol MP, Zar HJ, Tena-Coki NG, Kampmann B. Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries. *Sci Rep* 2018; 8: 15309.
- 53 Mangtani P, Nguipod-Djomo P, Keogh RH, et al. The duration of protection of school-aged BCG vaccination in England: a population-based case-control study. *Int J Epidemiol* 2018; 47: 193–201.
- 54 Nguipod-Djomo P, Haldal E, Rodrigues LC, Abubakar I, Mangtani P. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. *Lancet Infect Dis* 2016; 16: 219–26.
- 55 Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. *Health Technol Assess* 2013; 17: 1–372, v–vi.
- 56 Rhodes SJ, Knight GM, Fielding K, et al. Individual-level factors associated with variation in mycobacterial-specific immune response: gender and previous BCG vaccination status. *Tuberculosis (Edinb)* 2016; 96: 37–43.
- 57 Mangtani P, Nguipod-Djomo P, Keogh RH, et al. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. *Health Technol Assess* 2017; 21: 1–54.
- 58 Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. *Clin Infect Dis* 1995; 20: 982–91.
- 59 Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA* 1994; 271: 698–702.
- 60 Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. *Lancet* 1995; 346: 1339–45.
- 61 Faust L, Schreiber Y, Bocking N. A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities. *BMC Public Health* 2019; 19: 1504.
- 62 Altes HK, Dijkstra F, Lugnèr A, Cobelens F, Wallinga J. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment. *Epidemiology* 2009; 20: 562–68.
- 63 Brewer TF, Heymann SJ, Colditz GA, et al. Evaluation of tuberculosis control policies using computer simulation. *JAMA* 1996; 276: 1898–903.
- 64 Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. *Lancet* 2006; 367: 1173–80.
- 65 Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. *Int J Tuberc Lung Dis* 2004; 8: 392–402.
- 66 Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics* 1995; 96: 29–35.
- 67 Rosenthal SR, Leslie EI, Loewinson E. BCG vaccination in all age groups; methods and results of a strictly controlled study. *J Am Med Assoc* 1948; 136: 73–79.
- 68 Ferguson RG, Simes AB. BCG vaccination of Indian infants in Saskatchewan. *Tubercle* 1949; 30: 5–11.
- 69 Basu Roy R, Sotgiu G, Altet-Gómez N, et al. Identifying predictors of interferon- γ release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guérin? a pTB-NET collaborative study. *Am J Respir Crit Care Med* 2012; 186: 378–84.
- 70 Katelaris AL, Jackson C, Southern J, et al. Effectiveness of BCG vaccination against *Mycobacterium tuberculosis* infection in adults: a cross-sectional analysis of a UK-based cohort. *J Infect Dis* 2020; 221: 146–55.
- 71 Nemes E, Geldenhuis H, Rozot V, et al. Prevention of *M. tuberculosis* infection with H4:IC31 vaccine or BCG revaccination. *N Engl J Med* 2018; 379: 138–49.

- 72 Chaves-Carballo E, Sanchez GA. Regional lymphadenitis following BCG vaccination (BCGitis). Clinical comments based upon 25 instances among 1295 childhood vaccinees. *Clin Pediatr (Phila)* 1972; 11: 693–97.
- 73 Grange JM. Complications of bacille Calmette-Guérin (BCG) vaccination and immunotherapy and their management. *Commun Dis Public Health* 1998; 1: 84–88.
- 74 Hassanzad M, Valinejadi A, Darougar S, Hashemitari SK, Velayati AA. Disseminated Bacille Calmette-Guérin infection at a glance: a mini review of the literature. *Adv Respir Med* 2019; 87: 239–42.
- 75 Yang TL, Lee CM, Lee KL, et al. Clinical features of tuberculosis and Bacillus Calmette-Guérin (BCG)-associated adverse effects in children: a 12-year study. *J Formos Med Assoc* 2021; 120: 443–51.
- 76 Lotte A, Wasz-Höckert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. *Adv Tuberc Res* 1984; 21: 107–93.
- 77 Bernatowska EA, Wolska-Kusniercz B, Pac M, et al. Disseminated bacillus Calmette-Guérin infection and immunodeficiency. *Emerg Infect Dis* 2007; 13: 799–801.
- 78 Hesseling AC, Johnson LF, Jansen H, et al. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. *Bull World Health Organ* 2009; 87: 505–11.
- 79 WHO. BCG vaccine: WHO position paper, February 2018—recommendations. *Vaccine* 2018; 36: 3408–10.
- 80 Casanova JL, Blanche S, Emile JF, et al. Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective study. *Pediatrics* 1996; 98: 774–78.
- 81 Yadav RM, Dalvi A, Gupta M, et al. Spectrum of inborn errors of immunity in a cohort of 90 patients presenting with complications to BCG vaccination in India. *Scand J Immunol* 2021; 93: e13010.
- 82 Casanova JL. Mendelian susceptibility to mycobacterial infection in man. *Swiss Med Wkly* 2001; 131: 445–54.
- 83 Taur PD, Gowri V, Pandrowala AA, et al. Clinical and molecular findings in mendelian susceptibility to mycobacterial diseases: experience from India. *Front Immunol* 2021; 12: 631298.
- 84 Mahdavian SA, Mansouri D, Jamee M, et al. Mendelian susceptibility to mycobacterial disease (MSMD): clinical and genetic features of 32 Iranian patients. *J Clin Immunol* 2020; 40: 872–82.
- 85 Ratnatunga CN, Lutzky VP, Kupz A, et al. The rise of non-tuberculosis mycobacterial lung disease. *Front Immunol* 2020; 11: 303.
- 86 Lenis AT, Lec PM, Chamie K. Bladder cancer. *JAMA* 2020; 324: 2006.
- 87 Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. *J Urol* 1976; 116: 180–83.
- 88 Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. *Medicine (Baltimore)* 2014; 93: 236–54.
- 89 Liu Y, Lu J, Huang Y, Ma L. Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Guérin for bladder cancer. *J Oncol* 2019; 2019: 6230409.
- 90 Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. *Clin Infect Dis* 2000; 31 (suppl 3): S86–90.
- 91 Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of *Mycobacterium bovis* BCG vaccine strains to antituberculous antibiotics. *Antimicrob Agents Chemother* 2009; 53: 316–18.
- 92 Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. *Nat Rev Urol* 2018; 15: 615–25.
- 93 Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. *BMJ* 1995; 311: 481–85.
- 94 Kristensen I, Aaby P, Jensen H, Fine P. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. *BMJ* 2000; 321: 1435–38.
- 95 Higgins JP, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. *BMJ* 2016; 355: i5170.
- 96 Biering-Sørensen S, Aaby P, Lund N, et al. Early BCG-Denmark and neonatal mortality among infants weighing <2500 g: a randomized controlled trial. *Clin Infect Dis* 2017; 65: 1183–90.
- 97 Prentice S, Nassanga B, Webb EL, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. *Lancet Infect Dis* 2021; 21: 993–1003.
- 98 Jayaraman K, Adhisivam B, Nallasivan S, et al. Two randomized trials of the effect of the Russian strain of Bacillus Calmette-Guérin alone or with oral polio vaccine on neonatal mortality in infants weighing <2000 g in India. *Pediatr Infect Dis J* 2019; 38: 198–202.
- 99 Scholtz-Buchholzer F, Biering-Sørensen S, Lund N, et al. Early BCG vaccination, hospitalizations, and hospital deaths: analysis of a secondary outcome in 3 randomized trials from Guinea-Bissau. *J Infect Dis* 2019; 219: 624–32.
- 100 Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis. *Lancet Infect Dis* 2006; 6: 162–70.
- 101 Zimmermann P, Finn A, Curtis N. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis. *J Infect Dis* 2018; 218: 679–87.
- 102 The Uganda Buruli Group. BCG vaccination against *Mycobacterium ulcerans* infection (Buruli ulcer). First results of a trial in Uganda. *Lancet* 1969; 1: 111–15.
- 103 Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG against *Mycobacterium ulcerans* disease: a controlled trial in an endemic area of Uganda. *Trans R Soc Trop Med Hyg* 1976; 70: 449–57.
- 104 Scholtz-Buchholzer F, Berendsen M, Roth A, et al. BCG skin reactions by 2 months of age are associated with better survival in infancy: a prospective observational study from Guinea-Bissau. *BMJ Glob Health* 2020; 5: e002993.
- 105 Storgaard L, Rodrigues A, Martins C, et al. Development of BCG scar and subsequent morbidity and mortality in rural Guinea-Bissau. *Clin Infect Dis* 2015; 61: 950–59.
- 106 Stensballe LG, Ravn H, Birk NM, et al. BCG vaccination at birth and rate of hospitalization for infection until 15 months of age in Danish children: a randomized clinical multicenter trial. *J Pediatric Infect Dis Soc* 2019; 8: 213–20.
- 107 Berendsen MLT, Øland CB, Bles P, et al. Maternal priming: Bacillus Calmette-Guérin (BCG) vaccine scarring in mothers enhances the survival of their child with a BCG vaccine scar. *J Pediatric Infect Dis Soc* 2020; 9: 166–72.
- 108 Benn CS, Fisker AB, Rieckmann A, Sørup S, Aaby P. Vaccinology: time to change the paradigm? *Lancet Infect Dis* 2020; 20: e274–83.
- 109 Aaby P, Andersen A, Ravn H, Zaman K. Co-administration of BCG and diphtheria-tetanus-pertussis (DTP) vaccinations may reduce infant mortality more than the WHO-schedule of BCG first and then DTP. A re-analysis of demographic surveillance data from rural Bangladesh. *EBioMedicine* 2017; 22: 173–80.
- 110 Rieckmann A, Villumsen M, Sørup S, et al. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971–2010. *Int J Epidemiol* 2017; 46: 695–705.
- 111 Kühtreiber WM, Tran L, Kim T, et al. Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. *NPJ Vaccines* 2018; 3: 23.
- 112 Ristori G, Romano S, Cannoni S, et al. Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. *Neurology* 2014; 82: 41–48.
- 113 Faustman DL. Benefits of BCG-induced metabolic switch from oxidative phosphorylation to aerobic glycolysis in autoimmune and nervous system diseases. *J Intern Med* 2020; 288: 641–50.
- 114 Gofrit ON, Klein BY, Cohen IR, Ben-Hur T, Greenblatt CL, Bercovier H. Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients. *PLoS One* 2019; 14: e0224433.
- 115 Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, et al. Activate: randomized clinical trial of BCG vaccination against infection in the elderly. *Cell* 2020; 183: 315–323.e9.
- 116 Tsilika M, Taks E, Dolianitis K, et al. Activate-2: a double-blind randomized trial of BCG vaccination against COVID19 in individuals at risk. *MedRxiv* 2021; published online May 24. <https://doi.org/10.1101/2021.05.20.21257520>.

- 117 Goodridge HS, Ahmed SS, Curtis N, et al. Harnessing the beneficial heterologous effects of vaccination. *Nat Rev Immunol* 2016; 16: 392–400.
- 118 MacKanness GB. The immunological basis of acquired cellular resistance. *J Exp Med* 1964; 120: 105–20.
- 119 Mackness GB. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. *J Exp Med* 1969; 129: 973–92.
- 120 Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc Natl Acad Sci USA* 2012; 109: 17537–42.
- 121 Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. *Cell Host Microbe* 2011; 9: 355–61.
- 122 Moorlag SJCFM, Rodriguez-Rosales YA, Gillard J, et al. BCG vaccination induces long-term functional reprogramming of human neutrophils. *Cell Rep* 2020; 33: 108387.
- 123 Kaufmann E, Sanz J, Dunn JL, et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. *Cell* 2018; 172: 176–190.e19.
- 124 Cirovic B, de Bree LCJ, Groh L, et al. BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment. *Cell Host Microbe* 2020; 28: 322–334.e5.
- 125 Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. *J Innate Immun* 2014; 6: 152–58.
- 126 Fanucchi S, Dominguez-Andres J, Joosten LAB, Netea MG, Mhlanga MM. The intersection of epigenetics and metabolism in trained immunity. *Immunity* 2021; 54: 32–43.
- 127 Chumakov K, Avidan MS, Benn CS, et al. Old vaccines for new infections: exploiting innate immunity to control COVID-19 and prevent future pandemics. *Proc Natl Acad Sci USA* 2021; 118: e2101718118.
- 128 Brazier B, McShane H. Towards new TB vaccines. *Semin Immunopathol* 2020; 42: 315–31.
- 129 Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. *Nature* 2020; 577: 95–102.
- 130 Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. *N Engl J Med* 2019; 381: 2429–39.
- 131 Munseri P, Said J, Amour M, et al. DAR-901 vaccine for the prevention of infection with *Mycobacterium tuberculosis* among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial. *Vaccine* 2020; 38: 7239–45.
- 132 Sharma SK, Katoch K, Sarin R, et al. Efficacy and safety of *Mycobacterium indicus pranii* as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. *Sci Rep* 2017; 7: 3354.
- 133 Kaufmann SHE. Vaccination against tuberculosis: revamping BCG by molecular genetics guided by immunology. *Front Immunol* 2020; 11: 316.
- 134 Loxton AG, Knaul JK, Grode L, et al. Safety and immunogenicity of the recombinant *Mycobacterium bovis* BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. *Clin Vaccine Immunol* 2017; 24: e00439–16.
- 135 Grode L, Ganoza CA, Brohm C, Weiner J, III, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. *Vaccine* 2013; 31: 1340–48.
- 136 Tameris M, Mearns H, Penn-Nicholson A, et al. Live-attenuated *Mycobacterium tuberculosis* vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. *Lancet Respir Med* 2019; 7: 757–70.
- 137 Spertini F, Audran R, Chakour R, et al. Safety of human immunisation with a live-attenuated *Mycobacterium tuberculosis* vaccine: a randomised, double-blind, controlled phase I trial. *Lancet Respir Med* 2015; 3: 953–62.
- 138 Manjaly Thomas ZR, McShane H. Aerosol immunisation for TB: matching route of vaccination to route of infection. *Trans R Soc Trop Med Hyg* 2015; 109: 175–81.
- 139 Lai R, Afkhami S, Haddadi S, Jeyanathan M, Xing Z. Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments. *Eur Respir Rev* 2015; 24: 356–60.
- 140 Verreck FAW, Tchilian EZ, Vervenne RAW, et al. Variable BCG efficacy in rhesus populations: pulmonary BCG provides protection where standard intra-dermal vaccination fails. *Tuberculosis (Edinb)* 2017; 104: 46–57.
- 141 WHO. Implementing the End TB Strategy: the essentials. Geneva: World Health Organization, 2015.

© 2021 Elsevier Ltd. All rights reserved.

